Point mutations in IDH1 and IDH2 are detected in different types of malignancies such as glioma and glioblastoma [1,2,3], acute myeloid leukemia (AML), and head and neck squamous cell carcinoma (HNSCC). This evidence concerns the gene IDH2 and glioma.